CRB’s Horizons series of industry reports pools the talents and expertise of our leading subject matter experts to understand the conditions and forces affecting the life sciences and food and beverage industries. Based on hundreds of surveys of industry leaders, our free reports go deep on the critical trends driving the markets and how companies can stay on the leading edge.
Horizons: Life Sciences 2026
download todayBacked by insights from more than 400 global R&D and manufacturing leaders, the Horizons: Life Sciences 2026 report reveals how the industry is committing capital, expanding into emerging modalities, and rethinking the skilled workforce to keep innovation moving forward — even without a surefire roadmap.
Horizons: Life Sciences 2025 report
From bold process strategies to groundbreaking modalities, discover how science, execution, and human drive are converging to shape the future.
Read More
Horizons: Life Sciences 2024 Report
This facility-focused report offers guidance to stay ahead in the rapidly evolving life sciences sector. Our subject matter experts examine how companies manage capital and operational spending in a challenging economic climate before exploring facility, equipment and process trends.
Read More
Horizons: Life Sciences 2023 report
Our fourth Horizons: Life Sciences report focuses on the similarities and differences between North America and Europe to examine the trends that will determine how quickly the next revolution in life-changing medicine will unfold.
Read More
Horizons: Life Sciences 2022 report
This report explores an industry that is investing in novel research, pushing against long-established comfort zones, and moving cautiously but steadily toward an advanced standard of care for critically ill patients.
Read More
Horizons: Life Sciences 2021 report
We explore the disruptive forces reshaping how biopharma companies speed life-saving therapies and vaccines to the market.
Read More
Horizons: Cell & Gene Therapy 2020 report
Through a survey of nearly 150 industry leaders, our inaugural CRB Horizons: Cell and Gene Therapy report finds the biopharma space at a critical inflection point.
Read More
